Search Results

You are looking at 1 - 10 of 539 items for :

  • "cisplatin" x
  • Refine by Access: All x
Clear All
Full access

Michael Xiang and Elizabeth A. Kidd

conclusions about outcomes in older women from randomized trials. Cisplatin is the preferred chemotherapeutic agent in patients with cervical cancer undergoing definitive CRT. 14 However, the added benefit of cisplatin in elderly women is unclear because of

Full access

Daniel Morgensztern and Ramaswamy Govindan

patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial . Eur J Cardiothorac Surg 2004 ; 26 : 173 – 182 . 10. Arriagada R Bergman B Dunant A . Cisplatin-based adjuvant chemotherapy in patients with completely

Full access

Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle

evidence base and longest clinical track record as the concurrent agent. Cisplatin and carboplatin are the primary platinum agents used in the treatment of H&N cancer. Despite early interest in carboplatin in the 1990s and its use in several large clinical

Full access

Matthew G. Fury and David G. Pfister

been linked to poor prognosis among individuals with squamous cell carcinoma of the buccal mucosa. 7 In a combined analysis of 2 randomized studies of cisplatin-based chemotherapy for patients with R/M HNSCC (n = 399; ECOG 1393 and ECOG 1395), 5 factors

Full access

Maurie Markman

intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy . Cancer Res 1989 : 49 : 3380 – 3384 . 10 Howell SB Pfeifle CE Wung WE . Intraperitoneal cisplatin with systemic thiosulfate protection . Ann

Full access

Presented by: Maura L. Gillison

Based on available data on de-escalation of therapy for patients with HPV-positive head and neck cancers, cisplatin and 70 Gy of intensity-modulated radiotherapy (IMRT) remain the standard of care (SoC) for these patients. No data currently

Full access

Pankaj Singhal and Shashikant Lele

Cancer J Clin 2005 ; 55 : 10 – 30 . 2. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the

Full access

David M. Brizel, William Lydiatt, and A. Dimitrios Colevas

, elimination of cisplatin-based concurrent systemic therapy, use of alternative systemic agents such as cetuximab, or an increased reliance on primary surgical therapy instead of (chemo)radiation have all been proposed. The crux of the debate is whether

Full access

Pooja Ghatalia and Elizabeth R. Plimack

urinary tract. Approximately 50% of patients with localized UC experience recurrence after cystectomy and approximately 4% present with metastatic UC (mUC) at diagnosis. 2 Cisplatin-based chemotherapy remains the standard first-line treatment for mUC, with

Full access

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

% to 80% and median survival times of 7 to 10 months. 4 , 5 These results led to the evaluation of many combination therapies, most notably cisplatin/etoposide (EP). Two phase III studies suggested improved clinical benefit with EP over nonplatinum